BioNTech and DualityBio Receive FDA Breakthrough Therapy

Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced...

Related Keywords

China ,Aizenberg ,Baden Wüberg ,Germany ,Shanghai ,United States ,Fosun Pharma ,Vivian Gu ,Genentech ,Business Development ,Drug Administration ,National Cancer Institute ,Duality Biologics Suzhou Co ,Exchange Commission ,Pfizer ,Roche Group ,End Results Program ,World Cancer Research Fund International ,Human Epidermal Growth Factor Receptor ,Breakthrough Therapy ,Chief Medical Officer ,Duality Immune Toxin Antibody Conjugates ,Hormone Receptor Positive ,New Technologies ,Duality Biologics ,Antibody Drug Conjugate ,Private Securities Litigation Reform Act ,Cancer Research Fund ,Natl Cancer ,Cancer Stat Facts ,Nasdaq Bntx ,Biontech Se ,Ntx ,Dualitybio ,Dc ,Fda ,Nt323 ,Endometrial Cancer ,Eb 228 Rmutterkrebs ,